Grail has appointed Hans Bishop as the firm's CEO. He succeeds Jennifer Cook, who has stepped down from the position for family health reasons. Bishop has served on the firm's board of directors since 2018 and will continue serving as its director. Bishop will also continue serving as executive chair of the Sana board of directors, as well as director of Celgene, Agilent Technologies, and Lyell Immunopharma. Bishop founded Juno Therapeutics in 2013 and served as the firm's president and CEO until it was acquired by Celgene in 2018. Prior to Juno, he served as executive in residence at Warburg Pincus. Before Warburg, Bishop served as executive VP and chief operating officer for Dendreon. Prior to Dendreon, he served as president of specialty medicine at Bayer Healthcare, senior VP of global commercial operations at Chiron, and VP and general manager of European Biopharmaceuticals.
Grail has also appointed Joshua Ofman as its chief of corporate strategy and external affairs. Prior to Grail, Ofman most recently served as senior VP of global health policy at Amgen. Before joining Amgen in 2003, Ofman was a member of the academic faculty at the University of California, Los Angeles School of Medicine, Cedars-Sinai Medicine Center. Ofman also served as senior VP of Zynx Health.
Grail has also appointed Maykin Ho to its board as an independent director. Ho is currently a venture partner of Qiming Venture Partners and a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong. She serves on the board of directors for FibroGen, Agios Pharmaceuticals, Parexel International, the Aaron Diamond AIDS Research Center, and the Institute for Protein Innovation. Ho is a retired partner of the Goldman Sachs Group, where she served as senior biotechnology analyst, co-head of healthcare for global investment research, and advisory director for healthcare investment banking. Before Goldman Sachs, Ho held various managerial positions at DuPont-Merck Pharmaceuticals and DuPont de Nemours & Company.
Grail also announced that Renée Galá has stepped down as the firm's CFO.